Arbutus Biopharma (ABUS) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Arbutus Biopharma

NasdaqGS•Healthcare•Biotechnology

$5.06+0.00(<0.01%)Market open

Market Cap

$999.20M

P/E

6.5x

P/S

5.5x

P/B

3.9x

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.

How this company scores

GoodMetricSide Score: 68/100

Strongest: Growth (23/25); weakest: Cash & Earnings Quality (8/25).

Profitability22/25

Growth23/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality8/25

Strengths

Growing revenueStrong marginsHigh ROERising earnings

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 6.5x5y range 5.2x – 6.5x

P/S · 5.5x5y range 4.4x – 107.9x

Currently below its 20-quarter median.

P/B · 3.9x5y range 2.1x – 11.6x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $999.20M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $181.72M
Q. Revenue: $1.01M
TTM EBITDA: $149.04M
TTM Op. Income: $149.00M
Q. Op. Income: $-5.96M
TTM Net Income: $153.05M
Q. Net Income: $-5.14M
EPS: $-0.03
Shares Out.: $197.47M

$181.72M in TTM revenue grew 1078.8% YoY, reaching $1.01M last quarter. TTM EBITDA of $149.04M and TTM operating income of $149.00M show growth is flowing through to the bottom line. TTM net income of $153.05M means revenue is converting into profit. Over the past year, TTM revenue is up 1079% — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: -587.1%
Op. Margin: -588.2%
Net Margin: -507.2%

Op. margin of -588.2% is down 602.0% YoY — costs are rising relative to revenue. Net margin at -507.2% Over the past year, operating margin is down 4345% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 6.5x
P/S Ratio: 5.5x
P/B Ratio: 3.9x

At 6.5x P/E, the stock trades below typical market levels. P/S of 5.5x and P/B of 3.9x provide additional context. P/E sits below typical market levels while revenue is growing. Over the past year, P/E is up 0% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $274.02M
Cash: $19.17M
Long-Term Debt: N/A
Book Value: $258.73M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-6.02M
TTM Free Cash Flow: $-24.63M
FCF Margin: -13.6%
FCF / Net Income: -0.2

TTM FCF of $-24.63M on $-6.02M in operating cash flow. The FCF / Net Income ratio of -0.2x means the business consumes cash — it is not yet self-funding. Across the last 8 quarters, free cash flow has risen for 4 consecutive quarters — an improving trend.